Drugs /

ima201

Back to Drugs List

Overview

Clinical Trials

View Clinical Trials for ima201

Ima201 has been investigated in 1 clinical trial, of which 1 is open and 0 are closed. Of the trial investigating ima201, 1 is phase 1 (1 open).

MAGEA4 Expression and MAGEA8 Expression are the most frequent biomarker inclusion criteria for ima201 clinical trials.

Malignant solid tumor is the most common disease being investigated in ima201 clinical trials [2].

Top Biomarker Inclusion Criteria for Open Clinical Trials Investigating Ima201
This graph displays the 20 most frequently occurring biomarkers curated on clinical trials investigating ima201 and the cancer types associated with these biomarkers. These numbers are derived from a set of 5,956 clinical trials for which biomarker status defines treatment.

Drug Details

Synonyms [2]:
autologous tcr-engineered t-cells ima201

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/. [2018-07-30] [2018-08-02].

2. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.